Hani Hassoun

Clinical trials

• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

  Principal investigator · Recruiting · Phase 2

  Memorial Sloan Kettering Cancer Center

  2023–2026
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

  Principal investigator · Completed · Phase 2

  Memorial Sloan Kettering Cancer Center

  2013–2024
• Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

  Principal investigator · Completed · Phase 2

  Memorial Sloan Kettering Cancer Center

  2011–2021
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

  Principal investigator · Completed

  Memorial Sloan Kettering Cancer Center

  2011–2019